Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
As delineated in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), a diagnostic classification of major depression necessitates the manifestation of a minimum of five symptoms over a span of at least two weeks
Who Is Most Likely To Benefit
Features Joint therapy approved by the FDA for both intravenous and intra-articular use, allowing treatment tailored to the veterinarian's preference and the horse's individual needs Millions of doses sold 5 More than 25 years of treatment success Safe and effective, proven by multiple studies Reduces production of inflammatory mediators, joint inflammation and the resulting lameness for at least 45 days after being given once a week for three weeks 4 Benefits Safe and effective 90% of cases treated intravenously judged to have excellent to good overall clinical improvement 1 96% of horses treated intra-articularly were judged to have excellent to good overall clinical improvement 1 Improvement can be seen after one dose Breaks the cycle of inflammation and lameness associated with synovitis Stimulates endogenous hyaluronic acid production 2 Decreases the presence of inflammatory mediators 4 Easy to use I.V
Without a concentration label, you risk dosing errors if you mix multiple peptides or use different reconstitution volumes across vials
